Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial.
Authors: Niemelä Tytti M, Tulamo Riitta-Mari, Aaltonen Kaisa, Sankari Satu M, Hielm-Björkman Anna K
Journal: BMC veterinary research
Summary
# Editorial Summary This randomised, double-blind clinical trial evaluated whether intra-articular injection of non-animal-stabilised hyaluronan (NASHA) altered synovial fluid biomarkers of cartilage degradation and inflammation at two weeks post-treatment, seeking to understand the biochemical effects of a commonly used joint therapeutic. Synovial fluid was analysed from horses receiving NASHA or placebo injections, with researchers measuring cartilage-derived biomarkers including CS846 alongside white blood cell counts and other inflammatory indicators. Whilst CS846 concentrations trended downward in the NASHA-treated group, no statistically significant differences emerged between treatment and control groups across any measured biomarkers, though synovial fluid white blood cell counts increased significantly following NASHA administration, suggesting a mild local inflammatory response. Despite this cellular reaction, horses showed no clinical adverse effects, indicating good tolerability of the intervention. For practitioners, these findings suggest that whilst NASHA appears safe for intra-articular use with no observable clinical complications, its biochemical effects on cartilage metabolism may be more subtle than anticipated, warranting longer-term follow-up studies to determine whether the observed biomarker trends translate into clinically meaningful joint protection.
Read the full abstract on PubMed
Practical Takeaways
- •IA hyaluronan (NASHA) appears safe for joint injection with good clinical tolerance, despite triggering a mild synovial inflammatory response on biomarker analysis
- •The lack of significant biomarker differences between treated and control groups suggests caution in assuming superiority of NASHA over placebo for modifying joint pathology in the short term
- •Monitor for transient synovial reaction after IA NASHA injection, though this does not appear to cause clinical problems in practice
Key Findings
- •Cartilage-derived biomarker CS846 decreased in the NASHA treatment group but showed no statistically significant difference compared to control
- •White blood cell count in synovial fluid increased significantly after intra-articular NASHA injection, suggesting a mild inflammatory response
- •No statistically significant treatment effects were observed for any biomarkers between treatment groups
- •Intra-articular NASHA was well tolerated with no clinical adverse effects observed